Novartis suspends production of 2 cancer treatments over quality concerns

Novartis is temporarily suspending production of Lutathera and Pluvicto over "potential quality issues identified in its manufacturing processes," it said May 5. 

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive